Evaluation of cardiac biomarkers and right ventricular dysfunction in patients with acute pulmonary embolism

Neşe Dursunoğlu, Dursun Dursunoğlu, Ali İhsan Yıldız, Simin Rota, Neşe Dursunoğlu, Dursun Dursunoğlu, Ali İhsan Yıldız, Simin Rota

Abstract

Objective: Right ventricular dysfunction (RVD) with myocardial damage may lead to fatal complications in patients with acute pulmonary embolism (PE). Cytoplasmic heart-type fatty acid-binding protein (HFABP) and the N-terminal fragment of its prohormone (NT-proBNP) are sensitive and specific biomarkers of myocardial damage. We evaluated RVD and cardiac biomarkers for myocardial damage and short-term mortality in patients with acute PE.

Methods: We analyzed 41 patients (24 females, 17 males) with confirmed acute PE prospective. Three groups (massive, submassive, and non-massive) of patients were defined, based on systemic systolic blood pressure measured on admission and RVD by transthoracic echocardiography (TTE). Also, systolic (s) and mean (m) pulmonary artery pressures (PAPs) were recorded by TTE, and plasma concentrations of cardiac troponin T (cTn-T), NT-proBNP, and HFABP were evaluated 6 month follow-up.

Results: Seventeen (41.5%) patients experienced a complicated clinical course in the 6-month follow-up for the combined end-point, including at least one of the following: death (n=12, 29.3%; 3 PE-related), chronic PE (n=4, 9.8%), pulmonary hypertension (n=2, 4.9%), and recurrent PE (n=1, 2.4%). Multivariate hazard ratio analysis revealed HFABP, NT-proBNP, and PAPs as the 6-month mortality predictors (HR 1.02, 95% CI 1.01-1.05; HR 1.01, 95% CI 1.01-1.04; and HR 1.02, 95% CI 1.02-1.05, respectively).

Conclusion: HFABP, NT-proBNP, and PAPs measured on admission may be useful for short-term risk stratification and in the prediction of 6-month PE-related mortality in patients with acute PE.

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Correlations between HFBAP and PaO2 and PAPs in patients with pulmonary embolism Pearson’s correlation test
Figure 2
Figure 2
Correlations between NT-proBNP and PaO2 and PAPs in patients with pulmonary embolism Pearson’s correlation test
Figure 3
Figure 3
Correlations between cTn-T and PaO2 and PAPs in patients with pulmonary embolism Pearson’s correlation test

References

    1. Gibler WB, Cannon CP, Blomkalns AL, Char DM, Drew BJ, Hollander JE, et al. Practical implementation of the Guidelines for Unstable Angina/Non-ST-Segment Elevation Myocardial Infarction in the emergency department. Ann Emerg Med. 2005;46:185–97.
    1. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of leftventricular systolic dysfunction. Lancet. 1998;351:9–13.
    1. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation. 2003;108:2191–4.
    1. Sohne M, Ten Wolde M, Buller HR. Biomarkers in pulmonary embolism. Curr Opin Cardiol. 2004;19:558–62.
    1. Kaczynska A, Pelsers M, Bochowicz A, Maciej K, Glatz JFC, Pruszczyk P. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta. 2006;371:117–23.
    1. Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C, et al. N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005;112:1573–9.
    1. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM. 2004;97:187–98.
    1. Ishii J, Ozaki Y, Lu J, Kitagawa F, Kuno T, Nakano T, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on the admission in the early hours of acute coronary syndrome. Clin Chem. 2005;51:1397–404.
    1. Pelsers MM, Hermens WT, Glatz JF. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005;352:15–35.
    1. Pruszczyk P, Bochowicz A, Maciej K, Torbicki A, Szulc M, Gurba H, et al. Myoglobin stratifies short-term risk in acute major pulmonary embolism. Clin Chim Acta. 2003;338:53–6.
    1. Cavallazzi R, Nair A, Vasu T, Marik PE. Natriuretic peptides in acute pulmonary embolism: a systematic review. Intensive Care Med. 2008;34:2147–56.
    1. Konstantinides S. Pulmonary embolism: impact of right ventricular dysfunction. Curr Opin Cardiol. 2005;20:496–501.
    1. Kucher N, Rossi E, De Rosa M, Goldbaher SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med. 2005;165:1777–81.
    1. Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G, et al. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008;29:1569–77.
    1. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J. 2008;29:2276–315.
    1. Ueti OM, Camargo EE, Ueti AA, de Lima-Filho EC, Nogueira EA. Assessment of right ventricular function with Doppler echocardiographic indices derived from tricuspid annular motion: comparison with radionuclide angiography. Heart. 2002;88:244–8.
    1. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography) J Am Soc Echocardiogr. 2003;16:1091–110.
    1. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877–905.
    1. Vieillard-Baron A, Page B, Augarde R, Prin S, Qanadli S, Beauchet A, et al. Acute cor pulmonale in massive pulmonary embolism: incidence, echocardiographic pattern, clinical implications and recovery rate. Intensive Care Med. 2001;27:1481–6.
    1. Sanchez O, Trinquart L, Planquette B, Couturaud F, Verschuren F, Caille V, et al. Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. Eur Respir J. 2013;42:681–8.
    1. Klok FA, Mos IC, Huisman MV. BNP levels in the prediction of adverse outcome in patients with pulmonary embolism: a meta-analysis. Am J Respir Crit Care Med. 2008;178:425–30.
    1. Coutance G, Le Page O, Lo T, Hamon M. Prognostic value of brain natriuretic peptide in acute pulmonary embolism. Crit Care. 2008;12:R109.
    1. Lega JC, Lacasse Y, Lakhal L, Provencher S. Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis. Thorax. 2009;64:869–75.
    1. Tulevski II, Mulder BJ, van Veldhuisen DJ. Utility of a BNP as a marker for RV dysfunction in acute pulmonary embolism. J Am Coll Cardiol. 2002;39:2080.
    1. Tulevski II, Ten Wolde M, van Veldhuisen DJ, Mulder JW, van der Wall EE, Buller HR, et al. Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism. Int J Cardiol. 2007;116:161–6.
    1. Alonso-Martínez JL, Annicchérico-Sánchez FJ, Urbieta-Echezarreta MA, Pérez-Ricarte S. N-terminal Pro-B type natriuretic peptide as long-term predictor of death after an acutepulmonary embolism. Med Clin (Barc) 2014 Jun 16;
    1. Özsu S, Özlu T, Şentürk A, Uçar EY, Kırkıl G, Kadıoğlu EE, et al. TUPEG Study Investigators. Combination and comparison of two models in prognosis of pulmonary embolism: results from TUrkey Pulmonary Embolism Group (TUPEG) study. Thromb Res. 2014;133:1006–10.
    1. Jiménez D, Kopecna D, Tapson V, Briese B, Schreiber D, Lobo JL, et al. On Behalf Of The Protect Investigators. Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2014;189:718–26.
    1. Gül EE, Can I, Güler I, Yeşildağ A, Abdülhalikov T, Kayrak M, et al. Association of pulmonary artery obstruction index with elevated heart-type fatty acid binding protein and short-term mortality in patients with pulmonary embolism at intermediate risk. Diagn Interv Radiol. 2012;18:531–6.
    1. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116:427–33.
    1. Goldhaber SZ. Assessing the prognosis of acute pulmonary embolism: tricks of the trade. Chest. 2008;133:334–6.
    1. Konstantinides S, Geibel A, Olschewski M, Kasper W, Hruska N, Jäckle S, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation. 2002;106:1263–8.
    1. Puls M, Dellas C, Lankeit M, Olschewski M, Binder L, Geibel A, et al. Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J. 2007;28:224–9.
    1. Dellas C, Puls M, Lankeit M, Schäfer K, Cuny M, Berner M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol. 2010;55:2150–7.
    1. Boscheri A, Wunderlich C, Langer M, Schoen S, Wiedemann B, Stolte D, et al. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J. 2010;160:294–300.
    1. Çetiner MA, Sayın MR, Yıldırım N, Karabağ T, Aydın M. The association of eccentricity indexes with cardiac biomarkers in normotensive acutepulmonary embolism patients: an observational study. Anatol J Cardiol. 2013;13:108–14.
    1. Kılınç G, Doğan OT, Berk S, Epöztürk K, Özşahin SL, Akkurt I. Significance of serum cardiac troponin I levels in pulmonary embolism. J Thorac Dis. 2012;4:588–93.
    1. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928–30.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner